NEWS & EVENTS:

> Intarcia Therapeutics, Inc. Preaents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions

> Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions

> Intarcia Completes Enrollment of Phase 1b Clinical Trial of ITCA 650 (DUROS delivery of exenatide) In Patients With Type 2 Diabetes